Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of ERY001 with gemcitabine or FOLFOX4 in second-line metastatic pancreatic adenocarcinoma
2013-004262-34Phase 2Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Feb 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of eryaspase in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by PHAXIAM Therapeutics. Primary endpoint: Progression-free survival rate at 16 weeks in ASNS 0–1 patients. Started Feb 2014; status: completed.
02
Drugs
eryaspase
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-004262-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004262-34.